IL134293A0 - Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances - Google Patents

Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances

Info

Publication number
IL134293A0
IL134293A0 IL13429398A IL13429398A IL134293A0 IL 134293 A0 IL134293 A0 IL 134293A0 IL 13429398 A IL13429398 A IL 13429398A IL 13429398 A IL13429398 A IL 13429398A IL 134293 A0 IL134293 A0 IL 134293A0
Authority
IL
Israel
Prior art keywords
preparation
active substances
peptides
antibiotic
linear
Prior art date
Application number
IL13429398A
Other languages
English (en)
Original Assignee
Synt Em Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synt Em Sa filed Critical Synt Em Sa
Publication of IL134293A0 publication Critical patent/IL134293A0/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13429398A 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances IL134293A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9710297A FR2767323B1 (fr) 1997-08-12 1997-08-12 Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
PCT/FR1998/001757 WO1999007728A2 (fr) 1997-08-12 1998-08-06 Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives

Publications (1)

Publication Number Publication Date
IL134293A0 true IL134293A0 (en) 2001-04-30

Family

ID=9510249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13429398A IL134293A0 (en) 1997-08-12 1998-08-06 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances

Country Status (7)

Country Link
EP (1) EP1003771A1 (xx)
JP (1) JP2001512739A (xx)
AU (1) AU754617B2 (xx)
CA (1) CA2298932A1 (xx)
FR (1) FR2767323B1 (xx)
IL (1) IL134293A0 (xx)
WO (1) WO1999007728A2 (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511466A (ja) * 1998-11-11 2003-03-25 パンセコ・アクティーゼルスカブ 修飾ｐｎａ分子
DK173006B1 (da) * 1998-11-11 1999-11-01 Ke Burgmann As Fremgangsmåde og anlæg til frembringelse af vægmateriale til brug ved fremstilling af kompensatorer, navnlig til røggaskanaler, samt kompensatormateriale og kompensator frembragt ved fremgangsmåden
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
FR2810985B1 (fr) * 2000-07-03 2004-12-24 Synt Em Peptides lineaires amphipathiques et les compositions les contenant
GB0103110D0 (en) 2000-08-25 2001-03-28 Aventis Pharma Inc A membrane penetrating peptide encoded by a nuclear localization sequence from human period 1
AU2002220979A1 (en) 2000-10-13 2002-04-22 Xigen Sa Intracellular delivery of biological effectors by novel transporter peptide sequences
US7033597B2 (en) * 2000-10-13 2006-04-25 Université de Lausanne Intracellular delivery of biological effectors
FR2821272B1 (fr) * 2001-02-23 2004-12-17 Synt Em Composes constitues d'une molecule analgesique liee a un vecteur capable de vectoriser ladite molecule a travers la barriere hematoencephalique et compositions pharmaceutiques les contenant
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
FR2829940A1 (fr) * 2001-09-27 2003-03-28 Synt Em Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central
CA2461575A1 (en) * 2001-10-16 2003-04-24 Synt:Em S.A. Use of peptide vectors to improve the immune response to antigens
FR2836474B1 (fr) * 2002-02-22 2004-12-24 Synt Em Composes, compositions et methode pour le transport des molecules de cyclosporine a travers la barriere hemato-encephalique
FR2840810B1 (fr) * 2002-06-18 2005-02-11 Synt Em Composition pour le transfert de molecules therapeutiques dans les poumons et leur utilisation pour le traitement des cancers du poumon et des maladies pulmonaires
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
FR2914928B1 (fr) * 2007-04-12 2009-07-10 Univ Victor Segalen Bordeaux 2 Procede de preparation d'un support pour l'immobilisation d'une cellule, ledit support et ses utilisations
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
ES2613866T3 (es) 2008-06-12 2017-05-26 Centre For Addiction And Mental Health Composiciones y métodos para modular la interacción y la función del receptor de dopamina D1-D2
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
US9150618B2 (en) 2010-10-14 2015-10-06 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT57992A (en) * 1988-10-21 1992-01-28 Magainin Sciences Inc Process for producing composition comprising biologically active peptides and certain anions
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
US5804558A (en) * 1993-07-20 1998-09-08 University Of California Protegrins
US5580852A (en) * 1993-12-17 1996-12-03 Pioneer Hi-Bred International, Inc. Derivatives of tachyplesin having inhibitory activity towards plant pathogenic fungi
DE69608816T2 (de) * 1995-11-16 2000-12-28 Shell Int Research Vernetzbare überzugszusammensetzungen von hydroxyfunktionellen dienpolymeren und verfahren zu ihrer herstellung
US5994306A (en) * 1995-11-22 1999-11-30 Intrabiotics Pharmaceuticals, Inc. Fine-tuned protegrins

Also Published As

Publication number Publication date
FR2767323A1 (fr) 1999-02-19
CA2298932A1 (fr) 1999-02-18
EP1003771A1 (fr) 2000-05-31
AU754617B2 (en) 2002-11-21
JP2001512739A (ja) 2001-08-28
AU8988998A (en) 1999-03-01
WO1999007728A2 (fr) 1999-02-18
FR2767323B1 (fr) 2001-01-05
WO1999007728A3 (fr) 1999-06-24

Similar Documents

Publication Publication Date Title
IL134293A0 (en) Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
AU3049397A (en) Cyclosporin-containing pharmaceutical composition
PL334976A1 (en) Pharmaceutic preparations containing amoxycyclin and clavulate
AU4894197A (en) Syringe, injector and injector system
EP0912549A4 (en) CONNECTIONS AND METHOD FOR PROVIDING ACTIVE PREPARATIONS AND THE USE THEREOF
PL320856A1 (en) Aerosol drug preparations
HUP0103793A3 (en) N-(2-aryl-propionyl)-sulfonamids, their use and pharmaceutical preparations containing them
AU7908098A (en) Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones
AU6729198A (en) Cosmetic preparations
AU3171997A (en) Cosmetic and/or pharmaceutical preparations
AU7840994A (en) Active substance delivery system
AU2870297A (en) Gas capsule and gas delivery system
AU1870497A (en) Buffer systems for use in stabilizing pharmaceutical preparations
IL125908A0 (en) Peptides and pharmaceutical compositions comprising same
AU4874997A (en) Nitric oxide donor drugs
AU2420997A (en) Oligopeptides for drug delivery
AUPN861496A0 (en) Lytic peptides
AUPO871997A0 (en) Dried biologically or therapeutically active preparations
AU5550296A (en) Conotoxin peptides
ZA9710435B (en) Stabilized pharmaceutical compositions based on quinupristine and on dalfopristine and their preparation.
AU4636396A (en) Antiglucocorticoid medicament
AU1733797A (en) Particulate carriers and pharmaceutical compositions containing the same
IL120239A0 (en) Macrocyclic peptides pharmaceutical composition containing them and their use
EP0967222A4 (en) CYCLIC DEPSIPEPTIDES AND MEDICINES CONTAINING THESE COMPOUNDS AS ACTIVE INGREDIENT
AU5416898A (en) Cisplatinum comprising pharmaceutical